Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketone Monitoring in T1D with Farxiga
NCT05541484Phase 4Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 1 diabetes mellitus (T1D), sponsored by Washington University School of Medicine. Primary endpoints: Capillary Blood Beta-hydroxybutyrate at 2 weeks and Breath Acetone at 2 weeks. Started Oct 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05541484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541484.